Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Korea ETF (EWY) vs Hims and Hers Health Inc (HIMS) Price & Performance

iShares MSCI South Korea ETFTrade
Hims and Hers Health IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Korea ETF vs Hims and Hers Health Inc — how do they compare? iShares MSCI South Korea ETF trades at $164.5, while Hims and Hers Health Inc trades at $34.28 (market cap $8.60B). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.

EWYHIMS
Sector
Broad Market / FactorHealth
52-Week High
$219.20$66.18
52-Week Low
$70.65$14.52
Market Cap
$8.60B
Enterprise Value
$8.98B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Korea ETF

EWY, the iShares MSCI South Korea ETF, is trading at $166.48, down 5.93% amid significant volatility in South Korean equities. Technical indicators show a bearish trend with strong selling pressure, while the underlying Kospi Index has experienced sharp declines from recent highs. The ETF remains heavily concentrated in Samsung and SK Hynix, making it highly sensitive to semiconductor and AI market dynamics.

The outlook remains challenging with ongoing volatility in chip stocks and foreign investor selling. While long-term AI demand provides potential upside, current market conditions suggest continued pressure. Key risks include single-stock concentration and global tech sector volatility, requiring careful risk management for investors.

Hims and Hers Health Inc

Hims & Hers Health trades at $35.52, up 1.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $33.57. Recent earnings show volatility with a Q1 2026 miss, but revenue grew to $2.35 billion in 2025. The company benefits from expansion in weight-loss therapies and a $400 million JPMorgan facility, though high valuations like a P/E of 57.14 and negative net income margin pose concerns.

Outlook is mixed: growth opportunities in telehealth and GLP-1 drugs support upside, but earnings inconsistency and regulatory risks from FDA reviews require caution. Analysts are 35% buy-rated, highlighting potential if execution improves, yet investors face volatility near key resistance at $38.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS